Cardiology · 57 min ago
miR-100-5p linked to lower postprandial triglyceride response via PCSK9
A study combining data from 32 healthy adults with cell and mouse experiments found that circulating miR-100-5p was associated with a lower post-meal triglyceride response. In experimental models, the microRNA reduced PCSK9 expression, and its administration lowered postprandial triglycerides in mice.
- miR-100-5p levels inversely tracked post-meal triglyceride response.
- The mimic reduced PCSK9 expression in HepG2 cells.
- Mimic treatment halved post-meal triglycerides in mice.
- Human findings are associative; clinical utility is unestablished.
Researchers assessed post-meal changes in circulating microRNAs in 32 healthy adults without dyslipidemia, comparing participants by the size of their triglyceride response. They also studied miR-100-5p in HepG2 and Caco2 cells and in mice given a miR-100-5p mimic. The study focused on postprandial triglycerides (PP-TG) and potential links to PCSK9 and triglyceride-rich lipoprotein uptake.
In the human participants, circulating miR-100-5p levels were inversely associated with the PP-TG response; the microRNA was preferentially associated with intestinal-origin triglyceride-rich particles in those with a lower response. In HepG2 cells, the mimic reduced PCSK9 mRNA by 52%, cellular protein by 28%, and PCSK9 secretion by 39%. Systemic delivery of the mimic halved postprandial triglycerides in mice; this effect was abolished by alirocumab.
The findings suggest a possible mechanism linking miR-100-5p and PCSK9 to post-meal lipid handling. However, the human findings are associative, and the intervention results come from cells and mice. The study does not establish miR-100-5p as a clinical biomarker or support changes to patient management.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Cardiovascular Research: miR-100-5p modulates postprandial triglyceride response by targeting PCSK9 ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.